

Jie Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3707325/publications.pdf>

Version: 2024-02-01

33
papers

596
citations

759233

12
h-index

642732

23
g-index

33
all docs

33
docs citations

33
times ranked

1043
citing authors

#	ARTICLE	IF	CITATIONS
1	Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. <i>Drug Design, Development and Therapy</i> , 2016, 10, 911.	4.3	77
2	Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 673.	3.5	52
3	Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. <i>Oncotarget</i> , 2017, 8, 34001-34017.	1.8	47
4	Health-related quality of life among rural men and women with hypertension: assessment by the EQ-5D-5L in Jiangsu, China. <i>Quality of Life Research</i> , 2019, 28, 2069-2080.	3.1	42
5	Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. <i>Cancer Medicine</i> , 2020, 9, 1683-1693.	2.8	41
6	Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7979-7992.	6.7	31
7	Development of drug-loaded chitosan hollow nanoparticles for delivery of paclitaxel to human lung cancer A549 cells. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1304-1313.	2.0	26
8	Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Therapeutics</i> , 2018, 40, 1122-1139.	2.5	26
9	Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension. <i>Pharmacoeconomics</i> , 2021, 39, 521-535.	3.3	26
10	Biodegradable Alginate-Chitosan Hollow Nanospheres for Codelivery of Doxorubicin and Paclitaxel for the Effect of Human Lung Cancer A549 Cells. <i>BioMed Research International</i> , 2018, 2018, 1-11.	1.9	24
11	Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2019, 94, 80-85.	1.5	21
12	A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 2020, 11, 619.	3.5	16
13	Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC. <i>Immunotherapy</i> , 2020, 12, 1067-1075.	2.0	15
14	Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0202563.	2.5	12
15	Efficacy and safety of Levetiracetam as adjunctive treatment in children with focal onset seizures: A systematic review and meta-analysis. <i>Epilepsy Research</i> , 2019, 153, 40-48.	1.6	12
16	Ixazomib – the first oral proteasome inhibitor. <i>Leukemia and Lymphoma</i> , 2019, 60, 610-618.	1.3	12
17	Preparation of a Novel Form of Gelatin With a Three-Dimensional Ordered Macroporous Structure to Regulate the Release of Poorly Water-Soluble Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2940-2948.	3.3	11
18	Histamine2-Receptor Antagonists, Proton Pump Inhibitors, or Potassium-Competitive Acid Blockers Preventing Delayed Bleeding After Endoscopic Submucosal Dissection: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1055.	3.5	11

#	ARTICLE	IF	CITATIONS
19	Preparation of a novel starch-derived three-dimensional ordered macroporous carbon for improving the dissolution rate and oral bioavailability of water-insoluble drugs. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 267-275.	2.8	10
20	Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e478-e488.	0.4	10
21	Estimated Stroke-Free Survival of Folic Acid Therapy for Hypertensive Adults. <i>Hypertension</i> , 2020, 75, 339-346.	2.7	10
22	Comparing the measurement properties of the EQ-5D-5L and the EQ-5D-3L in hypertensive patients living in rural China. <i>Quality of Life Research</i> , 2021, 30, 2045-2060.	3.1	10
23	<p>A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4955-4973.	2.0	9
24	A Model of Interaction between Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Apocynin Analogues by Docking Method. <i>International Journal of Molecular Sciences</i> , 2013, 14, 807-817.	4.1	8
25	Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China. <i>European Journal of Health Economics</i> , 2023, 24, 197-207.	2.8	8
26	Costâ€effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer. <i>Immunotherapy</i> , 2020, 12, 705-713.	2.0	7
27	Development of a novel starch with a three-dimensional ordered macroporous structure for improving the dissolution rate of felodipine. <i>Materials Science and Engineering C</i> , 2016, 58, 1131-1137.	7.3	6
28	Costâ€effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1237-1246.	2.0	6
29	Do health preferences differ among Asian populations? A comparison of EQ-5D-5L discrete choice experiments data from 11 Asian studies. <i>Quality of Life Research</i> , 2022, 31, 2175-2187.	3.1	5
30	Preparation of starch macrocellular foam for increasing the dissolution rate of poorly water-soluble drugs. <i>Pharmaceutical Development and Technology</i> , 2015, 21, 1-6.	2.4	4
31	Costâ€effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF&A receptor 2-negative breast cancer. <i>Immunotherapy</i> , 2021, 13, 661-668.	2.0	1
32	Abstract 198: Lifetime Clinical Benefit of Folic Acid Therapy for Primary Prevention of Stroke in Patients with Hypertension - Projection Based on the CSPPT. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, .	2.2	0
33	Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 352-352.	1.7	0